论文部分内容阅读
目的:探究恩替卡韦联合健肝灵治疗对慢性乙型肝炎的临床治疗效果。方法:选取自本院2013年4月至2014年6月本院收治的156例慢性乙型肝炎患者,分为观察组和对照组。分别采用恩替卡韦联合健肝灵和健肝灵,对患者进行治疗。采用放射免疫法对肝功能指标天门冬氨酸氨基转移酶(AST)、谷氨酸氨基转移酶(ALT)以及血清肝纤维化指标透明质酸(HA)、层黏连蛋白(LN)和IV型胶原(IV-C),进行检测,并采用荧光定量PCR方法对乙肝病毒的脱氧核糖核酸(HBV-DNA)进行检测。治疗前各项指标检测1次,治疗后也进行检测。结果:观察组在治疗前后的肝功能指标(AST、ALT)、血清肝纤维化指标HA、LN和IV-C、HBV-DNA以及乙型肝炎e抗原(HBe Ag)阴转率等方面的改善情况均好于对照组,差异具有统计学意义(P<0.05)。结论:恩替卡韦联合健肝灵治疗慢性乙型肝炎的临床治疗效果好于单用健肝灵的治疗效果,且各项指标改善均很明显。
Objective: To investigate the clinical effect of entecavir combined with jianganling on chronic hepatitis B. Methods: 156 patients with chronic hepatitis B admitted to our hospital from April 2013 to June 2014 were divided into observation group and control group. Patients were treated with entecavir combined with Jianganling and Jianganling respectively. Radioimmunoassay was used to detect the indexes of hepatic function such as AST, ALT and serum markers of hepatic fibrosis such as hyaluronic acid (HA), laminin (LN) and IV Collagen IV (IV-C) were detected, and the detection of hepatitis B virus DNA (HBV-DNA) by fluorescence quantitative PCR method. The indicators before treatment test 1, also tested after treatment. Results: The improvement of AST, ALT, HA, LN and IV-C, HBV-DNA and HBe Ag negative rate in the observation group before and after treatment The situation is better than the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical efficacy of entecavir combined with jianganling in treating chronic hepatitis B is better than that of jianganling alone, and the improvement of various indexes is obvious.